सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

pfizer private limited - methotrexate - tablet - 2.500 mg - methotrexate 2.500 mg

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - methotrexate - tablet - 2.5 mg - methotrexate 2.5 mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - methotrexate - oral tablet - 2.5mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - methotrexate - oral tablet - 2.5mg

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methotrexate - tablet - 2.5 milligram(s) - other immunosuppressants; methotrexate

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; polysorbate 80; microcrystalline cellulose; pregelatinised maize starch - antineoplastic chemotherapy: treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatolo

कनाडा - अंग्रेज़ी - Health Canada

teva canada limited - methotrexate (methotrexate sodium) - tablet - 2.5mg - methotrexate (methotrexate sodium) 2.5mg - antineoplastic agents

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; maize starch; polysorbate 80; microcrystalline cellulose; magnesium stearate - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultations. rheumatoid

कनाडा - अंग्रेज़ी - Health Canada

pharmascience inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

mantra pharma inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg